HCG vs Kisspeptin
FDA Approved vs Emerging
compatible Complementary mechanisms for HPG axis stimulation.
Molecular Data
HCG Kisspeptin
Weight 36,700 Da 1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Half-life 24-36 hours ~4 minutes (KP-10), ~28-32 minutes (KP-54)
Chain 237 amino acids (alpha: 92, beta: 145) 10-54 amino acids
Type Heterodimeric glycoprotein Neuropeptide family (RFamide)
Key Benefits
HCG
01 Maintains testicular function during TRT
02 Preserves fertility and prevents testicular atrophy
03 Stimulates endogenous testosterone production
04 Induces ovulation in women
05 FDA-approved for multiple indications
06 Well-established safety profile
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Dosing Protocols
HCG
250-1500 IU (lower for TRT adjunct, higher for fertility) / 2-3 times weekly, or every other day for lower doses
TRT Adjunct (Low) 250-500 IU Every other day
TRT Adjunct (Standard) 500-1000 IU Twice weekly
HCG Monotherapy 1500-2000 IU 2-3x weekly
Fertility (with FSH) 1500-2000 IU 2-3x weekly
Cryptorchidism (Pediatric) 1000-5000 IU 2-3x weekly for 3-4 weeks
Ovulation Trigger (Female) 5000-10,000 IU Single dose
PCT Protocol 1000-1500 IU Every other day for 2-3 weeks
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Side Effects
HCG
Gynecomastia (breast tenderness/swelling) due to increased estrogen
Headaches, irritability, and mood swings (especially initially)
Fluid retention and edema
Potential antibody formation with long-term use
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Contraindications
Hormone-sensitive cancers (prostate, breast)
Pregnancy (except as prescribed)
Precocious puberty risk in children
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Research Evidence
HCG Kisspeptin
Status FDA Approved Emerging
References 5 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.